In This Story
Replimune Group Inc. (REPL+18.54%) has submitted its 10-Q filing for the quarterly period ended September 30, 2024.
The filing includes financial statements for the quarter, showing a net loss of $53.1 million compared to $60.0 million in the same quarter the previous year. This decrease in net loss is attributed to lower research and development expenses.
Research and development expenses for the quarter were $43.4 million, down from $49.1 million in the previous year. The decrease is primarily due to reduced spending on the RP1, RP2, and RP3 programs.
Selling, general, and administrative expenses increased slightly to $15.5 million from $14.7 million, driven by increased personnel costs.
Replimune reported total other income of $5.9 million, up from $3.6 million in the previous year, primarily due to favorable foreign exchange rate fluctuations.
Cash and cash equivalents and short-term investments totaled $432.1 million as of September 30, 2024. The company expects these funds to support operations into the second half of 2026.
Replimune continues to focus on its proprietary RPx platform, including lead product candidate RP1, which is being developed for use in combination with checkpoint blockade therapies.
The company is conducting several clinical trials, including the IGNYTE trial for RP1 in combination with nivolumab, and a Phase 1b/2 trial for RP1 in solid organ transplant recipients with skin cancers.
Replimune anticipates increased expenses related to ongoing clinical trials and potential commercialization efforts, and acknowledges the need for additional capital to achieve its business objectives.
The filing also details collaborations with Bristol-Myers Squibb (BMY+1.20%) and Regeneron Pharmaceuticals (REGN+0.95%) for the supply of anti-PD-1 therapies to support the development of Replimune's product candidates.
Replimune faces risks related to product development, regulatory approval, and market competition, as well as the need to protect its intellectual property and manage its financial resources effectively.
This content was summarized by generative artificial intelligence using public filings retrieved from SEC.gov. The original data was derived from the Replimune Group Inc. quarterly 10-Q report dated November 12, 2024. To report an error, please email earnings@qz.com.